Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-12-20 Major Shareholding Noti…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for Nordnet AB (publ) in Vivesto AB, specifically noting that the threshold for a 'major shareholding notification' was crossed due to a 'New share issue'. It provides detailed tables showing 'Before the transaction' and 'After the transaction' holdings, including the resulting percentage (5.01% directly held shares, 5.19% total voting rights). This structure is characteristic of a notification regarding a significant change in ownership, which corresponds to the Major Shareholding Notification category.
2019-12-20 English
Slutligt utfall i Oasmias företrädesemission
Capital/Financing Update Classification · 98% confidence The document is a press release dated December 9, 2019, titled "Slutligt utfall i Oasmias företrädesemission" (Final outcome of Oasmia's rights issue). It details the subscription results of a rights issue, stating that the issue was fully subscribed, the amount of capital raised (approx. 399 MSEK), and the resulting increase in share capital and total number of shares. This content directly relates to the company's fundraising and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA/RNS), but the substantive announcement of the financing event's conclusion.
2019-12-09 Swedish
Final result of the rights issue in Oasmia
Capital/Financing Update Classification · 99% confidence The document is a press release dated December 9, 2019, announcing the "Final result of the rights issue in Oasmia." It details the subscription percentages, the total proceeds received (approximately SEK 399 million), the resulting increase in share capital, and the expected trading dates for the new shares. A rights issue is a specific type of corporate financing activity where existing shareholders are given the right to purchase additional new shares. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital structure event.
2019-12-09 English
Oasmias företrädesemission övertecknad
Capital/Financing Update Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and its main subject is the preliminary outcome of a rights issue ("företrädesemission") in Oasmia Pharmaceutical AB, stating it was oversubscribed. This announcement details capital structure changes (increase in share capital, number of shares) resulting from a financing activity. This clearly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a capital raise.
2019-12-09 Swedish
Oasmia’s rights issue has been oversubscribed
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated December 6, 2019, announcing the preliminary results of a rights issue for Oasmia Pharmaceutical AB. It details the subscription levels, the expected proceeds (SEK 399 million), and the resulting increase in share capital and total number of shares. A rights issue is a specific type of corporate action related to raising capital or changing the capital structure. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it mentions a prospectus was approved by the Swedish Financial Supervisory Authority, the document itself is the announcement of the outcome of the financing activity, not the prospectus or the final financial report.
2019-12-09 English
Oasmia offentliggör prospekt i samband med företrädesemission om cirka 399 MSEK samt uppdaterad information som återfinns i prospektet
Capital/Financing Update Classification · 95% confidence The document is a press release from Oasmia Pharmaceutical AB dated November 19, 2019, announcing the publication of a prospectus related to a rights issue (företrädesemission) of approximately 399 MSEK. It explicitly states that the prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) and provides links where the prospectus can be found. The document itself is an announcement about the availability of a formal offering document (the prospectus) and contains updated financial/legal information relevant to that offering. Since the core purpose is announcing the publication of a formal document (the prospectus) and providing details about the associated capital raising activity, it strongly aligns with 'Capital/Financing Update' (CAP) due to the focus on the rights issue, or potentially 'Report Publication Announcement' (RPA) because it announces the publication of the prospectus. However, the primary driver of the announcement is the capital raise itself (rights issue), which is a financing activity. Given the detailed context of the rights issue, CAP is the most specific fit, although RPA is also plausible if the focus were solely on the act of publishing the prospectus. Since the text details the financing amount (399 MSEK) and the nature of the offering (rights issue), CAP is the superior classification over a generic RPA.
2019-11-19 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.